Research programme: factor IX therapeutic - MDRNA

Drug Profile

Research programme: factor IX therapeutic - MDRNA

Latest Information Update: 25 Aug 2010

Price : $50

At a glance

  • Originator Nastech Pharmaceutical Company
  • Developer Marina Biotech
  • Class Blood coagulation factors
  • Mechanism of Action Factor IX stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Haemophilia

Most Recent Events

  • 25 Aug 2010 Discontinued for Haemophilia in USA (Parenteral)
  • 01 Apr 2010 MDRNA acquires Cequent Pharmaceuticals and is renamed Marina Biotech
  • 17 Apr 2008 Early research in Haemophilia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top